Preferred Label : tezspire;
Origin ID : M000754109;
Related record
https://www.has-sante.fr/jcms/p_3473151/fr/dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2023
France
guidelines for drug use
No Treatment for Diabetes
Nucala
Omalizumab
Borg Category-Ratio 10 Perceived Exertion Score 5
Omalizumab
Treat
tezspire
Treatment
Treatment Study
Severe Hallucination
Intensity and Distress 5
Severe Adverse Event
During Treatment
Epidermal cGVHD Score 4
Asthma
Dupilumab
asthma
Fasenra
Asthma Pathway
xolair
severe
Severe Dysplasia
asthma, nos
On Treatment
GDC Treatment Frequency Terminology
Treatment Epoch
Therapy Object
Dupixent
asthma
Biomaterial Treatment
Severe Extremity Pain
Mepolizumab
---
https://www.has-sante.fr/jcms/p_3479050/fr/tezspire-tezepelumab-asthme
2023
France
evaluation of the transparency committee
asthma
Asthma
tezepelumab
tezepelumab
tezspire
asthma
Tezepelumab
Asthma Pathway
asthma, nos
---
https://www.has-sante.fr/jcms/p_3402822/fr/tezspire-tezepelumab-asthme
2022
false
false
false
France
adult
adolescent
treatment outcome
insurance, health, reimbursement
tezepelumab
anti-asthmatic agents
injections, subcutaneous
antibodies, monoclonal, humanized
evaluation of the transparency committee
tezepelumab
tezspire
asthma
---
